Related Experiment Videos
Dermorphin inhibits spinal nociceptive flexion reflex in humans.
Brain Research
|April 23, 1986
Summary
Dermorphin (D), a frog-derived peptide, significantly increases pain tolerance in humans by acting on the spinal cord. Its analgesic effects are only partially reversed by naloxone, suggesting novel pain relief mechanisms.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Research
Background:
- Dermorphin (D) is a potent opiate-like peptide from frog skin.
- Animal studies show D has strong antinociceptive effects.
- Human analgesic properties of D remain uninvestigated.
Purpose of the Study:
- To investigate the analgesic properties of Dermorphin (D) in humans.
- To determine the spinal level of action for D's antinociceptive effects.
- To explore the interaction of D with opioid receptors.
Main Methods:
- Intravenous (i.v.) infusion of 0.16 mg/kg Dermorphin (D) in healthy volunteers.
- Assessment of nociceptive flexion reflex threshold.
- Administration of naloxone to antagonize D's effects, including in a chronic spinal subject.
Main Results:
- Dermorphin (D) induced a marked and long-lasting increase in nociceptive flexion reflex threshold in healthy volunteers.
- This antinociceptive effect was observed in a chronic spinal subject, indicating spinal action.
- Naloxone partially reversed (approx. 50%) the depressive effect of D on the spinal reflex.
Conclusions:
- Dermorphin (D) possesses significant analgesic properties in humans, acting primarily at the spinal level.
- The partial antagonism by naloxone suggests Dermorphin (D) may interact with distinct spinal opioid receptor populations.
- These findings open new avenues for understanding and developing novel analgesics.